PLAINSBORO, N.J., and BAGSVÆRD, Denmark, June 26, 2026
Novo Nordisk announced it will present new clinical and scientific findings across its haemophilia portfolio at the International Society on Thrombosis and Haemostasis (ISTH) Congress 2026, taking place July 11–15 in Paris, France. The presentations will highlight the investigational denecimig (Mim8) program together with new data for concizumab (Alhemo®), reinforcing the company’s continued investment in rare bleeding disorders. The programme includes Phase 3 clinical results, patient-reported outcomes, real-world evidence and preclinical research supporting future treatment strategies.
Phase 3 FRONTIER4 Highlights Denecimig Performance
The congress will feature multiple analyses from the Phase 3 FRONTIER4 study evaluating the long-term efficacy and safety of denecimig (Mim8) in children, adolescents and adults with haemophilia A, with or without inhibitors. Researchers will present results across once-weekly, once-every-two-weeks and once-monthly prophylactic dosing, demonstrating treatment flexibility while maintaining bleed prevention. Additional presentations will examine thrombin generation, patient-reported outcomes, dosing consistency and long-term safety data, further supporting denecimig’s development as a next-generation prophylactic therapy.
Explorer10 Expands Pediatric Evidence for Concizumab
Novo Nordisk will also present the first Phase 3 explorer10 results evaluating concizumab (Alhemo®) in children up to 11 years of age with haemophilia A or B and inhibitors. The oral presentation will include efficacy, safety and pharmacokinetic findings after 32 weeks of treatment. Additional scientific posters will explore concizumab’s mechanism of action, tissue factor pathway inhibitor biology and innovative laboratory monitoring approaches. Although pediatric use below 12 years remains investigational, these data represent an important milestone toward expanding treatment options for younger patients.
Advertisement
Broad Hemophilia Portfolio Strengthens Rare Disease Leadership
Beyond its lead clinical programs, Novo Nordisk will present real-world studies, physician preference analyses, patient-reported outcomes and health economic research aimed at improving haemophilia management. The company will also showcase preclinical research exploring denecimig’s potential in acquired haemophilia A and von Willebrand disease. Together, the extensive ISTH 2026 presentations reinforce Novo Nordisk’s more than 45-year commitment to rare blood disorders, highlighting its strategy to develop innovative therapies that improve long-term disease control and quality of life for patients living with haemophilia worldwide.
Source: Novo Nordisk press release
